LINCOLN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of LINCOLN PHARMACEUTICALS have increased by 13.76% YoY .
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 27.97 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LINCOLN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 531633|NSE : LINCOLN]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹581 Cr | ₹510 Cr | ₹472 Cr | ₹424 Cr | ₹386 Cr |
| Expenses | ₹481 Cr | ₹421 Cr | ₹377 Cr | ₹337 Cr | ₹321 Cr |
| Operating Profit (Excl OI) | ₹100 Cr | ₹89 Cr | ₹95 Cr | ₹87 Cr | ₹66 Cr |
| Other Income | ₹34 Cr | ₹22 Cr | ₹10.00 Cr | ₹5.66 Cr | ₹11 Cr |
| Interest | ₹1.47 Cr | ₹2.03 Cr | ₹1.45 Cr | ₹1.56 Cr | ₹2.02 Cr |
| Depreciation | ₹11 Cr | ₹9.17 Cr | ₹8.09 Cr | ₹7.56 Cr | ₹7.33 Cr |
| Profit Before Tax | ₹122 Cr | ₹100 Cr | ₹96 Cr | ₹84 Cr | ₹67 Cr |
| Profit After Tax | ₹93 Cr | ₹73 Cr | ₹69 Cr | ₹62 Cr | ₹51 Cr |
| Consolidated Net Profit | ₹93 Cr | ₹73 Cr | ₹69 Cr | ₹62 Cr | ₹51 Cr |
| Earnings Per Share (Rs) | ₹46.58 | ₹36.40 | ₹34.63 | ₹31.08 | ₹25.72 |
| PAT Margin (%) | 15.47 | 13.63 | 13.97 | 14.19 | 12.88 |
| ROE(%) | 17.04 | 15.59 | 17.35 | 18.32 | 17.67 |
| ROCE(%) | 22.53 | 21.82 | 24.29 | 24.90 | 22.30 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Key Financials |
||
| Market Cap | : | ₹ 1,569.8 Cr |
| Revenue (TTM) | : | ₹ 597.4 Cr |
| Net Profit(TTM) | : | ₹ 96.6 Cr |
| EPS (TTM) | : | ₹ 48.3 |
| P/E (TTM) | : | 16.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LINCOLN PHARMACEUTICALS | -3.8% | 24.7% | 31.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1% | 4.6% | 47.5% |
| CIPLA | -1.1% | -0.3% | 20.7% |
| DR REDDYS LABORATORIES | 2.2% | 12.1% | 21.6% |
| ZYDUS LIFESCIENCES | -2.7% | 0.8% | 43.8% |
| DIVIS LABORATORIES | 1% | -3.2% | 59.3% |
| MANKIND PHARMA | 0.8% | 12.8% | 52.4% |
| TORRENT PHARMACEUTICALS | -1.5% | 5.9% | 55% |
| LUPIN | 0.9% | 7.2% | 72.7% |
LINCOLN PHARMACEUTICALS Revenues
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 13.76 % |
| 5 Yr CAGR | 10.71 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹581 Cr | 13.76 | |
| Mar2023 | ₹510 Cr | 8.09 | |
| Mar2022 | ₹472 Cr | 11.30 | |
| Mar2021 | ₹424 Cr | 9.75 | |
| Mar2020 | ₹386 Cr | - | |
LINCOLN PHARMACEUTICALS Operating Profit
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 12.00 % |
| 5 Yr CAGR | 11.12 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹100 Cr | 12.00 | |
| Mar2023 | ₹89 Cr | -6.58 | |
| Mar2022 | ₹95 Cr | 9.52 | |
| Mar2021 | ₹87 Cr | 33.02 | |
| Mar2020 | ₹66 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.54 % |
| 5 Yr CAGR | 0.37 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 17.21% | -1.54 | |
| Mar2023 | 17.48% | -13.55 | |
| Mar2022 | 20.22% | -1.61 | |
| Mar2021 | 20.55% | 21.17 | |
| Mar2020 | 16.96% | - | |
LINCOLN PHARMACEUTICALS Profit After Tax
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 27.99 % |
| 5 Yr CAGR | 16.05 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹93 Cr | 27.99 | |
| Mar2023 | ₹73 Cr | 5.11 | |
| Mar2022 | ₹69 Cr | 11.41 | |
| Mar2021 | ₹62 Cr | 21.02 | |
| Mar2020 | ₹51 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 13.50 % |
| 5 Yr CAGR | 4.69 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 15.47 % | 13.50 | |
| Mar2023 | 13.63 % | -2.43 | |
| Mar2022 | 13.97 % | -1.55 | |
| Mar2021 | 14.19 % | 10.17 | |
| Mar2020 | 12.88 % | - | |
LINCOLN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 27.97 % |
| 5 Yr CAGR | 16.01 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹47 | 27.97 | |
| Mar2023 | ₹36 | 5.11 | |
| Mar2022 | ₹35 | 11.42 | |
| Mar2021 | ₹31 | 20.84 | |
| Mar2020 | ₹26 | - | |
LINCOLN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 531633|NSE : LINCOLN]
| Y-o-Y | 3.25 % |
| 5 Yr CAGR | 0.26 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 22.53% | 3.25 | |
| Mar2023 | 21.82% | -10.17 | |
| Mar2022 | 24.29% | -2.45 | |
| Mar2021 | 24.9% | 11.66 | |
| Mar2020 | 22.3% | - | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹784.9 |
| Current MarketCap | : | ₹ 1,569.8 Cr |
| Updated EOD on | : | Dec 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | -3.8% |
24.7% |
31.4% |
| SENSEX | -2.1% |
-2% |
11.3% |
LINCOLN PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 0.2% | 2.1% | 47.3% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE MIDSMALLCAP | -2.7% | 1.9% | 33.4% |
| S&P BSE SMALL CAP | -2.8% | 2.4% | 34.3% |
No NSE index found
You may also like the below Video Courses
FAQ about LINCOLN PHARMACEUTICALS Financials
How the annual revenues of LINCOLN PHARMACEUTICALS have changed ?
The Revenues of LINCOLN PHARMACEUTICALS have increased by 13.76% YoY .
How the Earnings per Share (EPS) of LINCOLN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of LINCOLN PHARMACEUTICALS has increased by 27.97 % YoY .
Check out Intrinsic Value of Peers of LINCOLN PHARMACEUTICALS
Compare Stock Analytics of Peers of LINCOLN PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
